噻托溴铵联合舒利迭对COPD患者肺过度充气及运动耐量的影响
发布时间：2018-07-17 19:50
【摘要】：目的评价联合吸入噻托溴铵及舒利迭(沙美特罗/丙酸氟替卡松干粉剂)对稳定期重—极重度COPD患者肺过度充气及运动耐量的影响。 方法42例稳定期重—极重度COPD患者随机分为联合吸入噻托溴铵及舒利迭组(联合治疗组,n=20)和舒利迭组(n=22)。联合治疗组吸入噻托溴铵干粉胶囊18gg,每天1次及沙美特/丙酸氟替卡松干粉剂(50μg/500μg1吸,每天2次；舒利迭组吸入沙美特罗/丙酸氟替卡松干粉剂(50μg/500μg)1吸,每天2次。在用药前及用药1月和3月后测定肺功能(IC、FRC、FEV1、FEV1%预计值及FEV1/FVC)、COPD评估测试(COPD assessment test, CAT)评分、呼吸困难评分、6分钟步行距离(6MWD),记录3月内AECOPD的情况,同时记录药物不良反应。 结果联合治疗组及舒利迭组治疗1月后IC为(1.72±0.01) Lvs (1.72±0.03) L, FRC为(3.35±0.19) Lvs (3.40±0.17) L;治疗3月后IC为(1.87±0.10) Lvs (1.76±0.13) L; FRC为(3.16±0.23) Lvs (3.35±0.16) L;治疗1月后IC及FRC两组比较差异无统计学意义(P0.05),治疗3月后两组比较差异有统计学意义(P0.05)。联合治疗组及舒利迭组治疗1月后6MWD为(197.13±15.03) mvs (187.83±16.70) m, CAT评分为(26.83±2.29) vs (29.96±2.29);治疗3月后6MWD%(215.43±13.88) mvs (211.17±13.67) m; CAT评分为(24.70±2.55) vs (26.43±2.11);6MWD及CAT评分在治疗1月及3月后两组比较差异均有统计学意义(P0.05),且随用药时间的延长改善作用更加显著。 结论联合吸入噻托溴铵及舒利迭能减轻稳定期重—极重度COPD患者肺过度充气(提高IC、降低FRC)、减轻呼吸困难、提高运动耐量、改善生活质量,较单独吸入舒利迭疗效更好。
[Abstract]:Objective to evaluate the effects of combined inhalation of tiotropium bromide and sulidide (salmeterol / fluticasone propionate dry powder) on pulmonary hyperventilation and exercise tolerance in patients with stable and extremely severe COPD. Methods 42 stable severe COPD patients were randomly divided into two groups: combined inhalation of tiotropium bromide, sulidide group (n = 20) and sulide group (n = 22). The combined treatment group inhaled thiotropium bromide dry powder capsule (18ggg, once a day) and salmete / fluticasone propionate dry powder (50 渭 g / 500 渭 g / day, 2 times a day), and sulidide group inhaled salmeterol / fluticasone propionate powder (50 渭 g / 500 渭 g), twice a day. Pulmonary function (ICFRC / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FVC) were measured before and 1 month and 3 months after administration. The scores of assessment test (cat), dyspnea score (6 MWD) and AECOPD within 3 months were recorded, and adverse drug reactions were recorded. Results the IC was (1.72 卤0.01) L vs (1.72 卤0.03) L, FRC was (3.35 卤0.19) L vs (3.40 卤0.17) L, IC was (1.87 卤0.10) L vs (1.76 卤0.13) L, FRC was (3.16 卤0.23) L vs (3.35 卤0.16) L in the combined treatment group and the sullide group, and there was no significant difference between the two groups after one month (P0.05). There was significant difference between the two groups after the month (P0.05). 6 MWD (197.13 卤15.03) mvs (187.83 卤16.70) m, cat score (26.83 卤2.29) vs (29.96 卤2.29), 6MWD% (215.43 卤13.88) mvs (211.17 卤13.67) m, cat score (24.70 卤2.55) vs (26.43 卤2.11) and cat score (24.70 卤2.55) vs (26.43 卤2.11) were significantly different between the two groups after one month and three months after treatment. (P 0.05), and with the prolongation of drug use time, the improvement was more significant. Conclusion combined inhalation of tiotropium bromide and sulipid can reduce lung hyperinflation (increase ICand reduce FRC), relieve dyspnea, improve exercise tolerance and improve quality of life in patients with stable and extremely severe COPD.
【学位授予单位】：兰州大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R563.9
本文编号：2130752
[Abstract]:Objective to evaluate the effects of combined inhalation of tiotropium bromide and sulidide (salmeterol / fluticasone propionate dry powder) on pulmonary hyperventilation and exercise tolerance in patients with stable and extremely severe COPD. Methods 42 stable severe COPD patients were randomly divided into two groups: combined inhalation of tiotropium bromide, sulidide group (n = 20) and sulide group (n = 22). The combined treatment group inhaled thiotropium bromide dry powder capsule (18ggg, once a day) and salmete / fluticasone propionate dry powder (50 渭 g / 500 渭 g / day, 2 times a day), and sulidide group inhaled salmeterol / fluticasone propionate powder (50 渭 g / 500 渭 g), twice a day. Pulmonary function (ICFRC / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FVC) were measured before and 1 month and 3 months after administration. The scores of assessment test (cat), dyspnea score (6 MWD) and AECOPD within 3 months were recorded, and adverse drug reactions were recorded. Results the IC was (1.72 卤0.01) L vs (1.72 卤0.03) L, FRC was (3.35 卤0.19) L vs (3.40 卤0.17) L, IC was (1.87 卤0.10) L vs (1.76 卤0.13) L, FRC was (3.16 卤0.23) L vs (3.35 卤0.16) L in the combined treatment group and the sullide group, and there was no significant difference between the two groups after one month (P0.05). There was significant difference between the two groups after the month (P0.05). 6 MWD (197.13 卤15.03) mvs (187.83 卤16.70) m, cat score (26.83 卤2.29) vs (29.96 卤2.29), 6MWD% (215.43 卤13.88) mvs (211.17 卤13.67) m, cat score (24.70 卤2.55) vs (26.43 卤2.11) and cat score (24.70 卤2.55) vs (26.43 卤2.11) were significantly different between the two groups after one month and three months after treatment. (P 0.05), and with the prolongation of drug use time, the improvement was more significant. Conclusion combined inhalation of tiotropium bromide and sulipid can reduce lung hyperinflation (increase ICand reduce FRC), relieve dyspnea, improve exercise tolerance and improve quality of life in patients with stable and extremely severe COPD.
【学位授予单位】：兰州大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R563.9
【参考文献】
相关期刊论文 前1条
1 郑劲平;康健;蔡柏蔷;周新;曹兆龙;白春学;钟南山;;吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较[J];中华结核和呼吸杂志;2006年06期
，本文编号：2130752
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2130752.html
最近更新
教材专著
